Differentiated Thyroid Gland Carcinoma clinical trials
13 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
- The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
- Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
- A Study of Avutometinib and Defactinib in People With Thyroid Cancer
- Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
- Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
- Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
- XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
- Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
- The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
- Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
- Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Differentiated Thyroid Gland Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.